Novel Class of Preventive Treatments for Migraine
Anti-calcitonin gene-related peptide monoclonal antibodies are the first approved pharmacologic treatments developed explicitly for the prevention of migraine.
Anti-calcitonin gene-related peptide monoclonal antibodies are the first approved pharmacologic treatments developed explicitly for the prevention of migraine.
Migraine attacks were more frequent in post-pubertal compared to pre-pubertal girls, with no observed difference in headache characteristics between the groups.
Researchers found that a poor night’s sleep may increase risk for migraine the following day, rather than the next morning.
Researchers posit that adult studies on headache can help to create a multidisciplinary treatment plan.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
Interventional pain modalities provide alternative analgesia in patients who are intolerant of pharmacologic agents, have comorbidities that require multiple medications, or have pain refractory to oral medications.
Researchers found data that showed women who are introverts have a propensity toward medication-overuse headache, rather than migraines.
The use of a smartphone-based progressive muscle relaxation was found to be associated with a reduction in monthly headache days and depression scores in patients with migraine.
Zonisamide, a sulfonamide anticonvulsant, demonstrated promising efficacy for the prophylactic treatment of chronic and episodic cluster headache disorders.
The FDA has approved Emgality (galcanezumab-gnlm; Lilly) for injection for the treatment of episodic cluster headache in adults.